L-Cells are the Functional Neuropod Cell in Human Gastrointestinal Tract and are Dysregulated in Inflammatory Bowel Disease (IBD)
Neuropod cells are a newly discovered type of enteroendocrine cell (EEC) that connect the gut and brain functionally into one circuit. In the mouse colon, neuropod cells express various peptide hormones, such as Pyy and Glp1, presynaptic proteins, and make synaptic contacts with sensory neurons. While their function is not fully elucidated, they play a […]
4 Resilient Dental Supply Players Positioned to Withstand Tariff Risks
The Zacks Medical – Dental Supplies industry in the Medical sector is entering the final quarter of 2025 with strong momentum and bright prospects for the next three months. Fueled by persistent innovation, an aging population with increasing healthcare needs, and a steady economic environment, both sectors are poised for continued growth and significant advancements. The […]
Product puzzle: food makers weigh up rise of GLP-1 drugs
The growing use of GLP-1 drugs presents opportunities for food manufacturers but what must NPD teams consider? The post Product puzzle: food makers weigh up rise of GLP-1 drugs appeared first on Just Food.
Jonathan Van Ness Addresses Backlash After Losing 70 Pounds on Weight-Loss Drug
Jonathan Van Ness is responding to the “gigantic conversation” around his decision to use a weight-loss drug after dropping 70 pounds since last year. On Thursday (October 30), the 38-year-old Queer Eye star took to TikTok to address criticism that he is no longer a “body positive person anymore” since he’s on a GLP-1 medication. […]
Jonathan Van Ness addresses ‘gigantic conversation’ around his weight loss after ‘medical issue’
The reality star began using a GLP-1 in September 2024
Ozempic and Wegovy protect the heart, even without weight loss
Semaglutide appears to safeguard the heart even when patients lose little weight. In a massive international trial, heart attack and stroke risk dropped by 20% regardless of BMI. The benefit seems tied not just to slimming down but to deeper biological effects on inflammation, blood pressure, and vessel health. Researchers say this could expand who qualifies for the drug.
Eli Lilly’s Sterling Results Highlight Rival Novo Nordisk’s Fading Fortunes
Eli Lilly dealt a George Foreman-worthy blow in its ongoing heavyweight title bout against Novo Nordisk for weight-loss drugmaker supremacy. The Indianapolis-based pharmaceutical company posted what many analysts pointed to as the strongest earnings of the season on Wednesday. Record performance of its GLP-1 drugs sent shares in Eli Lilly soaring, leaving its weight loss […]
GLP-1 Drugs Are Lowering America’s Obesity Rate
Mihai Andrei, ZME Science America’s obesity rates have constantly been rising. Over 40% of…
FDA approves pill which can prevent heart attack, stroke by reducing inflammation: How it works
The FDA has approved Rybelsus, the first oral GLP-1 receptor agonist, for managing cardiovascular risks in adults. This medication, previously for type 2 diabetes, now offers a needle-free option to reduce inflammation and oxidative stress, protecting heart and blood vessels. It also aids blood sugar and weight management, marking a significant advancement in preventative heart […]
Challenging Pfizer, Novo Nordisk Offers Up-to-$9B for Metsera
Intent on growing its leading position in obesity and weight management drugs, Novo Nordisk has made an unsolicited, approximately up-to-$9 billion bid for Metsera—more than a month after Pfizer announced its intent to buy the company for up to $7.3 billion. Novo Nordisk touched off a likely bidding war when it presented what Metsera’s board […]